Lighthouse Investment Partners LLC Takes $6.83 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Lighthouse Investment Partners LLC purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the second quarter, Holdings Channel.com reports. The firm purchased 420,000 shares of the company’s stock, valued at approximately $6,825,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Maple Rock Capital Partners Inc. increased its stake in shares of Teva Pharmaceutical Industries by 68.3% in the 1st quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after buying an additional 1,770,000 shares during the period. Glenview Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter worth about $16,752,000. Iron Triangle Partners LP raised its holdings in Teva Pharmaceutical Industries by 113.1% during the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock worth $39,083,000 after purchasing an additional 1,469,864 shares during the last quarter. Norges Bank acquired a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $14,376,000. Finally, Hsbc Holdings PLC boosted its stake in shares of Teva Pharmaceutical Industries by 242.6% in the 4th quarter. Hsbc Holdings PLC now owns 1,597,178 shares of the company’s stock valued at $16,667,000 after purchasing an additional 1,130,969 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 1.6 %

NYSE:TEVA opened at $17.74 on Friday. Teva Pharmaceutical Industries Limited has a 1 year low of $8.06 and a 1 year high of $19.08. The stock has a 50-day moving average price of $17.75 and a two-hundred day moving average price of $16.18. The stock has a market cap of $20.10 billion, a price-to-earnings ratio of -43.27, a PEG ratio of 1.23 and a beta of 0.88. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. The business had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. As a group, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the sale, the insider now owns 45,060 shares of the company’s stock, valued at approximately $777,285. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.55% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on TEVA. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. Barclays increased their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. Jefferies Financial Group upped their price objective on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.89.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.